For example, the combination of osimertinib and alisertinib, an aurora kinase A inhibitor, was used in a phase I clinal trail of EGFR-mutant lung cancer, and a randomized phase III clinical trial of alisertinib was performed for relapsed or refractory peripheral T-cell lymphoma [27,28,29]. This evidence concerns the gene EGFR and lung carcinoma.